The latest CGMs are definitely not cheap on the R&D side. The obvious implementation is really susceptible to interference from common drugs, which is a really expensive thing to fix. They're also trying to get wider adoption in the hospital which requires fixing similar issues with many different compounds. FDA is still quite tough on biocompatibility. They definitely are taking a good profit though.